Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HALO 
Halozyme Therapeutics Inc (HALO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: HALO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $76
1 Year Target Price $76
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.09% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.64B USD | Price to earnings Ratio 14.95 | 1Y Target Price 76 |
Price to earnings Ratio 14.95 | 1Y Target Price 76 | ||
Volume (30-day avg) 8 | Beta 1.16 | 52 Weeks Range 42.01 - 79.50 | Updated Date 10/14/2025 |
52 Weeks Range 42.01 - 79.50 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 47.28% | Operating Margin (TTM) 62.15% |
Management Effectiveness
Return on Assets (TTM) 21.21% | Return on Equity (TTM) 179.14% |
Valuation
Trailing PE 14.95 | Forward PE 8.19 | Enterprise Value 9346215540 | Price to Sales(TTM) 6.48 |
Enterprise Value 9346215540 | Price to Sales(TTM) 6.48 | ||
Enterprise Value to Revenue 7.93 | Enterprise Value to EBITDA 11.8 | Shares Outstanding 116966000 | Shares Floating 115528488 |
Shares Outstanding 116966000 | Shares Floating 115528488 | ||
Percent Insiders 1.16 | Percent Institutions 101.64 |
Upturn AI SWOT
Halozyme Therapeutics Inc
Company Overview
History and Background
Halozyme Therapeutics, Inc. was founded in 1998. It's a biopharmaceutical company focused on developing and commercializing novel oncology therapies and drug delivery technologies. Originally focused on enzyme technologies, Halozyme shifted its focus to oncology in recent years, acquiring Antares Pharma in 2022.
Core Business Areas
- Oncology: Development and commercialization of oncology therapies, including those leveraging its ENHANZE drug delivery technology.
- ENHANZE Drug Delivery Technology: Licensing its ENHANZE technology to pharmaceutical and biotechnology companies for subcutaneous delivery of biologics.
Leadership and Structure
Halozyme is led by Helen Torley, President and CEO. The company has a typical organizational structure with departments focused on research, development, commercial operations, and administration. It has a Board of Directors.
Top Products and Market Share
Key Offerings
- ENHANZE Technology: A drug delivery technology that enables subcutaneous administration of biologics that are usually administered intravenously. It is licensed to companies such as Roche, Bristol Myers Squibb and Takeda. Halozyme receives royalties and milestone payments. Competitors include other drug delivery technologies such as needle-free injection systems.
- PEGPH20 (for pancreatic cancer): PEGPH20 is a product candidate being evaluated in clinical trials for the treatment of pancreatic cancer. The approval of this drug would contribute significant revenue to the company. The drug has been shelved after failing to meet trial endpoints, resulting in a huge financial loss for the company.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition. Drug delivery technologies and oncology are high-growth areas.
Positioning
Halozyme is positioned as a leader in ENHANZE technology and is expanding its presence in the oncology space. Its competitive advantages include a proven drug delivery platform and strategic partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The global drug delivery market is estimated to reach $250 billion by 2027. The oncology market is projected to exceed $300 billion by 2028. Halozyme is positioned to capture a significant share through its ENHANZE platform and pipeline of oncology therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary ENHANZE drug delivery technology
- Strategic partnerships with major pharmaceutical companies
- Growing pipeline of oncology therapeutics
- Experienced management team
Weaknesses
- Reliance on partners for product commercialization
- Clinical trial risks associated with oncology drug development
- Competition from other drug delivery technologies
- Dependence on few products for revenue.
Opportunities
- Expanding ENHANZE partnerships
- Acquiring or licensing new oncology assets
- Developing novel drug delivery technologies
- Geographic expansion
Threats
- Failure of clinical trials
- Regulatory hurdles
- Patent expiration
- Competition from biosimilars
Competitors and Market Share
Key Competitors
- Catalent (CTLT)
- West Pharmaceutical Services (WST)
- Ligand Pharmaceuticals (LGND)
Competitive Landscape
Halozyme has a strong position with its ENHANZE platform, but faces competition from other drug delivery technologies and companies in the oncology space. CTLT focuses on development and manufacturing while West Pharmaceutical Services provides drug packaging. Ligand Pharmaceuticals provides technology that helps companies discover and develop medicines.
Major Acquisitions
Antares Pharma
- Year: 2022
- Acquisition Price (USD millions): 960
- Strategic Rationale: Strategic Rationale: Acquisition of Antares Pharma broadens Halozyme's portfolio, enhances its drug delivery capabilities and expands its commercial presence.
Growth Trajectory and Initiatives
Historical Growth: Halozyme has experienced significant revenue growth driven by ENHANZE licensing and royalties. The acquisition of Antares Pharma further accelerated growth.
Future Projections: Analysts project continued revenue growth driven by expanding ENHANZE partnerships and potential approvals of oncology therapeutics. Growth is expected to moderate as partnerships mature.
Recent Initiatives: Recent initiatives include expansion of the ENHANZE platform through new partnerships and clinical development of oncology assets. Acquisition of Antares Pharma in 2022.
Summary
Halozyme Therapeutics demonstrates strong growth potential through its ENHANZE technology and strategic acquisitions. Its success relies heavily on its partner's performances and the successful navigation of clinical trials. While the company exhibits a robust financial position, the reliance on a limited number of products warrants careful monitoring, and expansion into newer partnerships could lead to higher revenues. Risks include regulatory hurdles and competition within the drug delivery market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence. Data is based on the most recently available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Halozyme Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-03-16 | President, CEO & Director Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 350 | Website https://halozyme.com |
Full time employees 350 | Website https://halozyme.com | ||
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.